Evotec (EVO) said Thursday it expects 2025 revenue of 840 million euros to 880 million euros ($953.9 million to $999.3 million).
Four analysts polled by FactSet expect 851.4 million euros.
The AI-powered medical data collation firm said it expects a 2024 to 2028 compound annual growth rate of 8% to 12%.
Furthermore, the company said tariffs and potential US government funding cuts are expected to have a "limited impact" on its business. It is also planning to simplify its business model and reduce its asset portfolio by around 30%.
Additionally, Evotec plans to use automation and cost-lowering initiatives to produce around 50 million euros in gross savings by 2028 on top of a priority reset that is expected to deliver 40 million euros a year in savings.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.